More on BRONJ.

J Am Dent Assoc

Associate Chief of Staff and Director, Graduate Medical Education, Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, CA; Professor-in-Residence, Oral & Maxillofacial Surgery, UCLA Dental School, Los Angeles, CA; Director, Quality Assurance, Hospital Dental Service, Ronald Reagan UCLA Medical Center, Los Angeles, CA.

Published: October 2016

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.adaj.2016.08.016DOI Listing

Publication Analysis

Top Keywords

bronj
4
bronj
1

Similar Publications

Zoledronic Acid Regulates Osteoclasts via miR-483-5p in the BRONJ.

Oral Dis

January 2025

State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China.

Objectives: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a severe complication of bisphosphonate therapy, with unclear mechanisms. This study investigates the regulatory impact of zoledronic acid (ZOL) on osteoclasts and microRNA (miRNA) expression.

Materials And Methods: Raw264.

View Article and Find Full Text PDF

Local Single-Dose Teriparatide Administration for BRONJ Prevention: Insights from a Rat Model Study.

J Maxillofac Oral Surg

December 2024

Dental Implants Research Center, Dental Research Institute, School of Dentistry, Isfahan University of Medical Sciences, Hezar Jerib Avenue, Isfahan, Iran.

Background: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) presents significant clinical challenges with uncertain treatment outcomes. Teriparatide, a fragment of human parathyroid hormone, shows potential in prevention strategies for BRONJ.

Objective: This study investigates the impact of a single local dose of teriparatide on BRONJ prevention in an animal model.

View Article and Find Full Text PDF

The overview was carried out to evaluate the impact of antiresorptive drug (ARD) therapy in patients undergoing dental implant treatment who significantly experience medication-related osteonecrosis of the jaw (MRONJ) or not. A comprehensive electronic database search within the timeline of 2014-2024, restricted to the English language, was performed in database search engines like Google Scholar, Web of Science, PubMed, and Scopus. The articles were screened using the specific Medical Subject Headings (MeSH) terms and Boolean operators 'OR' and 'AND'.

View Article and Find Full Text PDF

Targeting endoplasmic reticulum stress-induced lymphatic dysfunction for mitigating bisphosphonate-related osteonecrosis.

Clin Transl Med

November 2024

Department of Oral and Maxillofacial Surgery, The Affiliated Hospital of Stomatology, Nanjing Medical University, Nanjing, China.

Background: Bisphosphonates (BPs) are the first-line treatment to stop bone resorption in diseases, including osteoporosis, Paget's disease, multiple myeloma and bone metastases of cancer. However, BPs-related osteonecrosis of the jaw (BRONJ), characterized by local inflammation and jawbone necrosis, is a severe intractable complication. The cumulative inflammatory burden often accompanies impaired lymphatic drainage, but its specific impact on BRONJ and the underlying mechanisms remain unclear.

View Article and Find Full Text PDF

Medication-related osteonecrosis of the jaw (MRONJ) refers to the condition where the maxillary or mandibular bone becomes exposed and necrotic as a result of bisphosphonate therapy. The number of patients on bisphosphonates is increasing and so are the MRONJ cases. Since the initial data were published in the early 2000s, research into MRONJ has expanded significantly to enhance the understanding of this emerging condition.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!